Aims-To describe the expression of three genes involved in the regulation of cell proliferation and programmed cell death (apoptosis) in normal, dysplastic and malignant large bowel epithelium, and to relate any alterations to important biological and clinical variables. Methods-Immunohistochemistry was used to assess bcl-2, c-myc and p53 gene expression in 70 colorectal carcinomas, 36 adenomas and three samples of normal mucosa. Results-Bcl-2 and c-myc protein were detected in all samples of normal mucosa and most adenomas. P53 was never found in normal mucosa and was expressed in only 5% of adenomas. Sixty nine of 70 carcinomas expressed c-myc protein; p53 was found in 46% and bcl-2 was present in 35%. Bcl-2 expression correlated with a higher degree of tumour differentiation whereas the opposite was true for c-myc. Strong staining for c-myc protein predicted survival in univariate analysis. No correlation was found between p53 and bcl-2 expression. Conclusions-While c-myc and bcl-2 proteins are overexpressed at an early stage of the large bowel adenoma-carcinoma sequence, alterations to the p53 protein level only occur as a late event in large, highly dysplastic adenomas and carcinomas. Bcl-2 may therefore protect the growing adenoma against excessive programmed cell death and mutated p53 may play a similar role in carcinomas. In vitro there is a reciprocal relation between p53 and bcl-2 expression. This could not be confirmed in vivo. Similarly, there was no relation between bcl-2 and c-myc status, despite evidence that these proteins cooperate to cause neoplastic transformation. C-myc may be a prognostic indicator in large bowel cancer. There is no evidence in the present series that bcl-2 status will affect survival.
Tumour growth, whether benign or malignant, results from an imbalance of cell production and cell loss. While there are many studies of cell proliferation in the literature, little is known about the other side of the equation. In 1977, Steel calculated that in some malignancies, including large bowel cancer, the rate at which new cells were produced was almost equalled by the rate of spontaneous cell loss.' Consequently, any factor which alters tumour cell loss, either by increasing cell death or exfoliation, could have a profound influence on tumorigenesis.
One of the most important mechanisms of tumour cell loss is apoptosis or programmed cell death.2 This is an active cellular process occurring both physiologically and pathologically in response to a number of specific stimuli. A low level of apoptosis is seen in the normal large bowel, where apoptotic bodies are commonly observed in the surface epithelium. 3 In disease states, such as drug induced colitis and graft versus host disease, the level of apoptosis may be increased. 4 5 Apoptotic bodies are also commonly seen in adenomas and malignant large bowel tumours, where they may be numerous and no longer confined to the epithelial surface.
Recent work suggests that several genes are involved in mediating programmed cell death. 6 Intriguingly, some of these are already known to be regulators of cell proliferation and differentiation, suggesting that the decision whether a cell divides or dies involves closely related pathways. Three particularly important mediators of apoptosis are the oncogenes bcl-2 and c-myc and the tumour suppressor gene p53.
Bcl-2, located at chromosome locus 1 8q, encodes a 26 kilodalton protein which resides in the mitochondrial membrane, endoplasmic reticulum and nuclear envelope.7 8 When expressed in lymphocytes it prolongs cell survival and rescues them from apoptosis induced by a variety of agents. 9 In transgenic mice overexpression results in polyclonal expansion of B lymphocyte populations and, subsequently, the development of monoclonal, high grade lymphoma' " Neoplastic transformation in these mice is frequently accompanied by activation of the c-myc oncogene, suggesting cooperation between bcl-2 and c-myc in tumorigenesis."' Supporting evidence for this hypothesis has been found in vitro.'2 '3 One possible reason for the cooperative effect between bcl-2 and c-myc, is the ability of bcl-2 to inhibit programmed cell death induced by the p62c-mYc oncoprotein. Recently, bcl-2 expression has been described in both normal and neoplastic bcl-2 gene may therefore play a role in epithelial tumours as well as haematological malignancy.
C-myc, the gene encoding a 62 kilodalton nuclear protein, is frequently deregulated in colorectal tumours.'6 '7 Sixty to 80% of carcinomas express elevated levels of myc protein and RNA transcript, similar levels also being found in a proportion of adenomas. While the c-myc gene is intimately involved in regulating cell proliferation, recent studies suggest that under certain circumstances it will also trigger apoptosis.'8 This is particularly the case when a cell receives conflicting signals to replicate and become quiescent at one and the same time.
A third gene implicated in the control of both cell division and programmed cell death is the p53 tumour suppressor gene. Located on the short arm of chromosome 17, p53 is inactivated in over 60% of carcinomas by a combination of chromosomal deletion and point mutation.'920
In large bowel cancer many of these mutations are missense mutations, producing an altered protein with an extended half-life which accumulates in the cell nucleus and becomes demonstrable by immunocytochemistry.2' This provides a simple immunohistochemical marker by which most, though not all, p53 mutations can be identified. 22 Shaw et aP3 recently showed that wild-type p53, in addition to causing cell cycle arrest, can also stimulate programmed cell death in a colorectal carcinoma cell line. This effect may be at least partially mediated by bcl-2, as p53 is capable of down-regulating the bcl-2 gene as well as inducing bax expression, a bcl-2 related protein with apoptosis promoting properties.24 P53 is also important in stimulating apoptosis in response to radio-and chemotherapy.25 26 Thus, there is a complicated molecular network by which programmed cell death and cell replication are integrated in the normal cell. Key elements in this regulatory system are provided by the bcl-2, c-myc and p53 genes, the last two of which are commonly altered in colorectal tumours. Little is known about bcl-2 expression in large bowel cancer as yet, although two recent studies suggest that the protein is present in a proportion of carcinomas. '4 15 In addition, there is evidence that bcl-2 and c-myc cooperate in some tumours to produce neoplastic transformation and that p53 may influence bcl-2 expression at the level of gene transcription.
In two previous reports we described overex Overexpression of p26bcl-2 in adenomas was characterised not only by intense cytoplasmic staining, but more importantly by the extension of staining up the crypt sides into the middle and upper third crypt compartments (fig 3) . In some cases bcl-2 could also be visualised in the surface epithelium. Reminiscent of normal mucosa, however, expression in some polyps was often most intense at the adenomatous crypt base.
Six microadenomas from the patients with FAP also showed raised bcl-2 protein levels. No difference in staining was seen, however, between the background mucosa of the FAP colon and either normal mucosa or mucosa from patients with sporadic adenomas.
Five metaplastic polyps showed staining confined to cells at the crypt base identical with that seen in normal mucosa. None of these polyps exhibited dysplasia.
C-MYC
Of the 70 carcinomas, only one failed to express p62cmYc. Thirty seven per cent showed weak or equivocal staining, 33% moderate and 28.6% strong staining. In 10% of cases the staining was predominantly nuclear (fig 4) . Forty five per cent showed cytoplasmic immunoreactivity, while the remainder expressed p62c-rYc in both the nucleus and cytoplasm (fig 5) . Table 1 shows the relation between c-myc expression and several clinicopathological variables. A trend was seen towards stronger staining in poorly differentiated carcinomas and tumours metastatic to regional lymph nodes (Dukes' stage C). Only the latter reached statistical significance however. Survival analysis showed shorter disease-free survival of patients with strongly staining tumours (p < 0.04), but the pattern of staining-that is, nuclear versus cytoplasmic, did not influence prognosis. All 21 adenomas exhibited some degree of immunostaining for c-myc. This was intense in five. The majority showed a mixture of nuclear and cytoplasmic expression, although nuclear staining was particularly conspicuous at the crypt base (fig 6) . There was no obvious relation between intensity of staining and polyp size, architectural type or degree of dysplasia. Expression was also seen in normal mucosa along the full length of the crypt, in lymphocytes and plasma cells, and in proliferating fibroblasts.
P53
Data for p53 staining were derived from two previous studies.27 2' Forty six per cent of carcinomas and 5% of adenomas overexpressed p53 protein. All staining was nuclear. Details of the relation between p53 and colorectal tumour behaviour have been reported previously.27 28 -1h-'-.Ds Figure 6 Mixed nuclear and cytoplasmic stainingfor c-myc oncoprotein in a colorectal adenoma. Note nuclear staining at the crypt base and cytoplasmic staining further up the crypt (x400).
No correlation was found in the present study between p53, bcl-2 and c-myc status (table 1) . Increased expression of one did not seem to be associated with overexpression of another.
Discussion
Carcinomas of the large bowel develop as a result of the accumulation of multiple genetic insults, many of which involve oncogenes and tumour suppressor genes.39 In the normal cell these genes function in the regulation of cell proliferation and differentiation, and tumorigenesis is thought to occur as a consequence of deregulated cell division. More recently, however, attention has focused on another class of oncogene which promotes neoplastic transformation by extending cell survival. Genes which play a role in the regulation of cell death by apoptosis include bcl-2, bcl-x, bax, c-myc, p53, and ras.6 Apoptosis is a common mode of cell loss in tumours, where it occurs both spontaneously and as a result of cytotoxic therapy.2 In some cancers the rate of spontaneous cell loss even approaches that of cell production. Consequently, genetic changes which protect a cell against programmed cell death may have a significant effect not only on the rate at which a tumour grows but also on the ability of tumour cells to survive in a hostile environment for example, within metastases.40 Several studies also suggest that alterations in genes regulating apoptosis influence the response of a cancer to chemotherapy. 2 26 41 42 Determining the status of p53 or bcl-2 in tumours may therefore eventually provide a more rational approach to adjuvant therapy. 43 The present study describes the immunohistochemical detection of the products of the bcl-2 and c-myc genes in a series of large bowel adenomas and carcinomas, and relates their expression to a third protein, p53. All of these genes influence apoptosis in vitro and p53 in particular seems to be an important regulator of programmed cell death in large bowel epithelium. 3 44 In normal and transitional mucosa p26bc-2 was restricted to the cytoplasm of a small number of cells at the crypt base. This is the location of the colonic crypt stem cells and it may be that bcl-2 is important in maintaining the integrity of this vital cell population. Identical staining was described by Lu et al45 and Hockenberry et al6, who confirmed their immunohistochemical findings by RNA in situ hybridisation. In contrast to normal mucosa, most adenomas exhibited increased protein expression with staining no longer confined to the crypt base, but extending into the upper half of the crypt. Even microadenomas from patients with FAP showed increased expression. Up-regulation of bcl-2 therefore seems to be an early feature of adenoma formation. Previous molecular studies have identified mutation of the APC gene and DNA hypomethylation as initiating events in the development of adenoma.47 The present study suggests that overexpression of bcl-2 is also associated closely with the earliest stages of neoplastic transformation in the large bowel. In this con-text it would be of interest to determine whether aberrant crypt foci also overexpress bcl-2, as these probably represent the earliest morphological lesion in large bowel carcinogenesis. 48 The extension of bcl-2 staining up the adenomatous crypt parallels the expanded proliferative compartment in these tumours.49 As many of the regulators of cell proliferation, such as c-myc, are also potent inducers of apoptosis and c-myc expression is abnormal in adenomas, up-regulation of bcl-2 may be necessary to protect the neoplastic clone from programmed cell death and permit adenoma growth. This would be consistent with the cooperative effect of bcl-2 and c-myc in vitro. Alternatively, it could be argued that raised bcl-2 expression is a secondary event and simply reflects increased cell proliferation. In 1986, Reed et ar0 showed that the bcl-2 gene is cell cycle regulated, although this has been disputed subsequently.5" While we cannot discount this mechanism in adenomas, the lack of a consistent relation between cell proliferation measurements and bcl-2 status in carcinomas in the present study suggests that overexpression may also occur independently of the cell cycle.
In carcinomas overexpression of p26bcI-2 was absent in all but 35% of tumours and only 10% showed diffuse immunoreactivity. This is different to the results found in two other immunohistochemical studies, in which over two thirds of carcinomas stained positively.'4 '5 28 56-58 As p53 also functions in apoptotic pathways in the cell, inactivation by mutation or allele loss may replace bcl-2 in protecting the cell against programmed cell death. Alternatively, accumulation of wildtype or mutant p53 protein, both of which are described in colorectal tumours, may switch off bcl-2 transcription directly. Negative regulation of bcl-2 by p53 has been described recently by several workers.24 59 If either of these were the case, one would expect a reciprocal relation between p53 and bcl-2 overexpression in carcinomas.While this has been documented in breast carcinoma, we could not confirm this in the large bowel.55 Sinicrope et al'5 reported similar findings in which the status of p53 and bcl-2 was unrelated in large bowel cancers but did seem to show a negative correlation in pre-malignant adenomas. In the current series only one adenoma overexpressed p53, making this kind of analysis impossible. Interestingly, however, this was the only polyp to show <5% tumour cell positivity for bcl-2.
A further genetic lesion which may supplement bcl-2 in extending cell survival is mutation of the ras oncogene, which also seems to have an anti-apoptotic effect.60 As over 40% of large adenomas and adenocarcinomas possess a mutated ras gene, this is therefore another potential candidate for inhibiting programmed cell death in the large bowel.6' 62 The results of immunohistochemical staining for p62c-mYc are similar to those reported by other authors.63 64 In conclusion, the development of colorectal cancer is a multistep process during which a series of genetic lesions accumulate. Many of these events involve oncogenes and tumour suppressor genes, several of which have been identified, and seem to be preferentially altered at different points in the adenoma-carcinoma sequence. In this study we have documented changes in the expression of the bcl-2 and c-myc proto-oncogenes, both of which are overexpressed in adenomas. While c-myc expression persists in the majority of carcinomas however, expression of bcl-2 is absent in all but complex interaction between genes regulating cell proliferation, differentiation and programmed cell death will provide new insights into the mechanism of large bowel carcinogenesis and may eventually guide the selection of cytotoxic therapy in these and other tumours.
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